SwitzerlandSwitzerland

A new prostate cancer blood test

08.02.2011

Zurich – Researchers headed by Wilhelm Krek from ETH Zurich have presented a new strategy for biomarker-based diagnosis of prostate cancer. The researchers said their two-step approach is generally suitable for discovery of serum biomarker signatures corresponding to cancer-causing mutations and subsequent verification (Proc. Natl. Acad Sci USA, doi/10.1073/pnas.1013699108. Comparing wild-type and Pten-null mice’s serum proteins by quantitative proteomics, Krek et al. identified 775 N-linked glycoprotein serum biomarkers. Pten is a prostate cancer biomarker and one of the tumour-suppressors most commonly inactivated in human cancers. From this subproteome, they identified relevant proteins leading to PTEN inactivation in humans. By comparison of the relevant biomarkers with serum proteins occurring in 143 patients with prostate cancer or benign prostatic hyperplasia, they identified 39 ortholog human proteins. Bioinformatic prioritisation of the potential signatures led to a 4-protein diagnostic signature that showed 79% specificity and 85% sensitivity in distinguishing patients with prostate cancer and benign prostatic hyperplasia. The researchers say the signature is suitable for staging of prostate cancer in combination with other diagnostic tests and could prevent current PSA-based over-diagnosis of prostate cancer patients.

SwitzerlandSwitzerland

21.02.2012

Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...

SwitzerlandSwitzerland

26.01.2012

Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....

SwitzerlandSwitzerland

23.01.2012

Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...

SwitzerlandSwitzerland

19.12.2011

Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...

SwitzerlandSwitzerland

17.12.2011

Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...

SwitzerlandSwitzerland

14.12.2011

Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...

SwitzerlandSwitzerland

14.12.2011

Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...

SwitzerlandSwitzerland

22.11.2011

Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...

SwitzerlandSwitzerland

16.11.2011

Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/1/article/a-new-prostate-cancer-blood-test.html

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)3.26 SEK5.16%
  • OREXO (S)121.00 SEK4.54%
  • CO.DON (D)2.88 EUR4.35%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • EPIGENOMICS (D)3.06 EUR-8.38%

TOP

  • CELLECTIS (F)13.54 EUR112.6%
  • SANTHERA (CH)68.40 CHF107.3%
  • ADDEX (CH)4.40 CHF101.8%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.98 EUR-50.3%
  • VERONA PHARMA (UK)1.15 GBP-45.2%

TOP

  • SANTHERA (CH)68.40 CHF3009.1%
  • GW PHARMACEUTICALS (UK)439.50 GBP835.1%
  • PAION (D)2.80 EUR324.2%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events